Evidence map›Paper›PMID 25102011›Full record

ArticleGene therapy2014

Improved retroviral episome transfer of transcription factors enables sustained cell fate modification.

J W Schott, D Hoffmann, T Maetzig, F-J Müller, D Steinemann, D Zychlinski, T Cantz, C Baum, A Schambach

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Gene therapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. The interplay of post-translational modification and gene therapy.Drug design, development and therapy · 2016
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

J W Schott1] Institute of Experimental Hematology, Hannover Medical School, Hannover, Germany [2] Cluster of Excellence REBIRTH, Hannover Medical School, Hannover, Germany.
D Hoffmann1] Institute of Experimental Hematology, Hannover Medical School, Hannover, Germany [2] Cluster of Excellence REBIRTH, Hannover Medical School, Hannover, Germany.
T Maetzig1] Institute of Experimental Hematology, Hannover Medical School, Hannover, Germany [2] Cluster of Excellence REBIRTH, Hannover Medical School, Hannover, Germany.
F-J MüllerCenter for Integrated Psychiatry, Christian Albrechts University, Kiel School of Medicine, Kiel, Germany.
D Steinemann1] Cluster of Excellence REBIRTH, Hannover Medical School, Hannover, Germany [2] Institute of Cell and Molecular Pathology, Hannover Medical School, Hannover, Germany.
D Zychlinski1] Institute of Experimental Hematology, Hannover Medical School, Hannover, Germany [2] Cluster of Excellence REBIRTH, Hannover Medical School, Hannover, Germany.
T Cantz1] Cluster of Excellence REBIRTH, Hannover Medical School, Hannover, Germany [2] Translational Hepatology and Stem Cell Biology, Hannover Medical School, Hannover, Germany.
C Baum1] Institute of Experimental Hematology, Hannover Medical School, Hannover, Germany [2] Cluster of Excellence REBIRTH, Hannover Medical School, Hannover, Germany.
A Schambach1] Institute of Experimental Hematology, Hannover Medical School, Hannover, Germany [2] Cluster of Excellence REBIRTH, Hannover Medical School, Hannover, Germany [3] Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
Kiel University · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Retroviral vectors are versatile gene transfer vehicles widely used in basic research and gene therapy. Mutation of retroviral integrase converts these vectors into transient, integration-deficient gene delivery vehicles associated with a high degree of biosafety. We explored the option to use integration-deficient retroviral vectors to achieve transient ectopic expression of transcription factors, which is considered an important tool for induced cell fate conversion. Stepwise optimization of the retroviral episome transfer as exemplified for the transcription factor Oct4 enabled to improve both expression magnitude and endurance. Long terminal repeat-driven γ-retroviral vectors were identified as the most suitable vector architecture. Episomal expression was enhanced by epigenetic modifiers, and Oct4 activity was increased following fusion to a minimal transactivation motif of herpes simplex virus VP16. Based on kinetic analyses, we identified optimal time intervals for repeated vector administration and established prolonged expression windows of choice. Providing proof-of-concept, episomal transfer of Oct4 was potent to mediate conversion of human fibroblasts stably expressing Klf4, Sox2 and c-Myc into induced pluripotent stem cells, which were mainly free of residual Oct4 vector integration. This study provides evidence for suitability of retroviral episome transfer of transcription factors for cell fate conversion, allowing the generation of distinct patient- or disease-specific cell types.

Indexed as

Cell DifferentiationCell LineGenetic VectorsHumansInduced Pluripotent Stem CellsIntegrasesKruppel-Like Factor 4Octamer Transcription Factor-3PlasmidsRetroviridaeTranscription FactorsTransduction, GeneticIntegrasesKLF4 protein, humanKruppel-Like Factor 4Octamer Transcription Factor-3POU5F1 protein, humanTranscription Factors

Identifiers

PMID25102011
OpenAlexW1972978841

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.